Creative Biostructure to Present at AACR Annual Meeting 2024 | April 5-10, 2024 | Booth #2953 
COVID-19 VLP (S; Luciferase)(CBS-V927)
Inquiry
| Product Summary | |
|---|---|
| Name | COVID-19 VLP (S; Luciferase) |
Download Datasheet
|
|
| Cat No. | CBS-V927 |
| Source | Pseudotyped lentivirus |
| Virus Name | SARS-CoV-2 |
| Virus Family | Coronaviridae |
| Composition | S-his, Luciferase |
| Purity | 90% |
| Presentation | PBS |
| Description | It is the replication-incompetent particles in which the native, full-length COVID-19 S protein (with 6His-tag at its C-terminal) was pseudo-typed as the lentiviral particles’ surface envelope protein. The virus genome is not included. Instead it was replaced by a Luciferase under CMV promoter. It is mock lentivirus.This VLP binds to cells that express any S-protein binding receptor, like ACE2. When this binding occur, the VLP stay at surface of the cells and also can get into cells, then the luciferase signal can be detected. |
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Frequently Asked Questions
-
What expression systems do you use for your VLP products?
Our virus-like particles are produced from different expression systems such as E. coli, yeast, insect cells, and HEK293 cells.
